

A decorative wave graphic that starts as a blue curve on the left, rises to a peak in the center, and then descends as an orange curve on the right.

## **Notice to holders of undated unsubordinated unsecured bonds convertible into new shares and/or exchangeable for existing shares and notice to holders of bonds convertible into new shares and/or exchangeable for existing shares**

### **(Suspension of the right to exercise share allotment/exchange rights during the current exercise period)**

Holders of undated unsubordinated unsecured bonds convertible into new shares and/or exchangeable for existing shares (the “**ODIRNANES**”) (ISIN: FR0014005AO4) and holders of bonds convertible into new shares and/or exchangeable for existing shares due 2027 (the “**OCEANES**”) (ISIN: FR0013489739) of Clariane (the “**Company**”) are informed that, in accordance with the provisions of Articles L. 225-149-1 and R. 225-133 of the French Commercial Code and in accordance with the terms and conditions of the ODIRNANES and OCEANES, and taking into account the decision of the Combined General Meeting of the Company's shareholders on 26 March 2024, which in particular delegated its authority to the Board of Directors to carry out a capital increase with preferential subscription rights for shareholders, the Board of Directors of the Company decided to suspend the conversion/exchange right attached to the ODIRNANES and OCEANES in issue, with effect from 10 June 2024 (00:01 a.m., Paris time) for a maximum period of three months, i.e. until 9 September 2024 (11:59 p.m., Paris time) at the latest.

The date of resumption of the right to exercise the conversion/exchange right may, if appropriate, be set at any other date within the aforementioned three-month period and will be specified in another notice published subsequently in the *Bulletin des Annonces Légales Obligatoires*.

The rights of holders of ODIRNANES and OCEANES who have not exercised their convert/exchange rights before this date will be preserved in accordance with the applicable legal and regulatory provisions and the terms and conditions of the ODIRNANES and OCEANES as the case may be.

## Disclaimer

This document does not constitute, and shall not be deemed to constitute, an offer to the public or an offer to buy or the solicitation of public interest in a transaction by way of public offer, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful absent registration or approval under the securities laws of such state or jurisdiction. The distribution of this document may be subject to specific restrictions in certain countries. Persons in possession of this document are required to inform themselves of and to observe any such local restrictions. Clariane's shares (and any rights to subscribe for shares in the Company) have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**U.S. Securities Act**"), and may not be offered or sold in the United States in the absence of applicable registration or an exemption from registration under the U.S. Securities Act, or in a transaction not subject to such requirements.

An admission prospectus relating to the reserved capital increase has been approved by the French Financial Markets Authority (*Autorité des marchés financiers*).

A prospectus relating to the capital increase with preferential subscription rights will be submitted by Clariane S.E. to the French Financial Markets Authority (*Autorité des marchés financiers*) for approval prior to the effective launch of this capital increase.

